Anticoagulant treatment and risk of adverse outcomes among hospitalized COVID-19 patients [Funder: MI4]
- Funded by Other Funders (Canada)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Other Funders (Canada)Principal Investigator
Filion, KristianResearch Location
Canada, South KoreaLead Research Institution
McGill UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
Blood thinning drugs may be an important treatment for COVID-19. New evidence shows that those with severe cases of COVID-19 develop abnormal blood clotting that can endanger their lives. Dr. Kristian Filion and his team, which includes several collaborators from Sungkyunkwan University in South Korea, are combing through a Korean health care database to determine whether administering anti-coagulant (blood thinning) drugs to COVID-19 patients eases their symptoms and increases chances of survival. If the research team determines that anti-coagulation drugs are effective, they could be a new tool to treat severe cases of COVID-19.